XML 51 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Development and License Agreements - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Oct. 31, 2023
May 31, 2021
Mar. 31, 2021
Sep. 30, 2019
Jun. 30, 2024
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Research and development expense         $ 23,485,000 $ 12,100,000   $ 47,189,000 $ 32,280,000
License and Stock Purchase Agreement | AbbVie                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Future milestone payment               0  
Non refundable upfront fee       $ 600,000          
License and Stock Purchase Agreement | AbbVie | Maximum                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Future payments upon the achievement of certain development       18,000,000          
Future payments upon commercialization       45,000,000          
Future payments upon sales based milestones       $ 87,500,000          
License Agreement | Roche                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Future milestone payment               0  
Non-refundable upfront payment   $ 4,000,000 $ 500,000            
Additional consideration upon achievement of certain development and commercial milestones     120,000,000            
License Agreement | Mabwell                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Future milestone payment $ 5,000,000                
Research and development expense         100,000 $ 0   100,000 $ 10,000,000
Upfront payment             $ 10,000,000    
License Agreement | Mabwell | Maximum                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Certain development and regulatory milestone payments         127,500,000     127,500,000  
Certain commercial milestone payments for certain licensed antibody product net sales achievements         $ 275,000,000     $ 275,000,000  
Development and Regulatory Milestone First Indication | License Agreement | Roche                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Contingent payments     50,000,000            
Development and Regulatory Milestone Second Indication | License Agreement | Roche                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Contingent payments     $ 35,000,000